{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T13:58:26Z","timestamp":1778162306543,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.dmpk.2023.100530","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T04:12:16Z","timestamp":1694751136000},"page":"100530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Quantitation and characterization of glucosylsphingosine in cerebrospinal fluid (CSF), plasma, and brain of monkey model with Gaucher disease"],"prefix":"10.1016","volume":"53","author":[{"given":"Sho","family":"Sato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmpk.2023.100530_bib1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1172\/JCI117084","article-title":"Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease","volume":"93","author":"Hollak","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.dmpk.2023.100530_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2003-05-1612","article-title":"Marked elevation of the chemokine CCL18\/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention","volume":"103","author":"Boot","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.dmpk.2023.100530_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079732","article-title":"Glucosylsphingosine is a highly sensitive and specific biomarker for primary diagnostic and follow-up monitoring in Gaucher disease in a non-Jewish, Caucasian cohort of Gaucher disease patients","volume":"8","author":"Rolfs","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.dmpk.2023.100530_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/acn3.177","article-title":"Progressive decline of glucocerebrosidase in aging and Parkinson's disease","volume":"2","author":"Rocha","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.dmpk.2023.100530_bib5","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1182\/blood-2011-05-352971","article-title":"Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response","volume":"118","author":"Dekker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.dmpk.2023.100530_bib6","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A\u00a0new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.dmpk.2023.100530_bib7","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.dmpk.2023.100530_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/acn3.292","article-title":"Ambroxol chaperone therapy for neuronopathic Gaucher disease: a pilot study","volume":"3","author":"Narita","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.dmpk.2023.100530_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/mt.2016.53","article-title":"CNS-accessible inhibitor of glucosylceramide synthase for substrate reduction therapy of neuronopathic Gaucher disease","volume":"24","author":"Marshall","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.dmpk.2023.100530_bib10","doi-asserted-by":"crossref","first-page":"8288","DOI":"10.1021\/acs.analchem.7b01442","article-title":"Glucosylceramide and glucosylsphingosine quantitation by liquid chromatography-tandem mass spectrometry to enable in\u00a0vivo preclinical studies of neuronopathic Gaucher disease","volume":"89","author":"Hamler","year":"2017","journal-title":"Anal Chem"},{"key":"10.1016\/j.dmpk.2023.100530_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.114852","article-title":"Highly-sensitive simultaneous quantitation of glucosylsphingosine and galactosylsphingosine in human cerebrospinal fluid by liquid chromatography\/tandem mass spectrometry","volume":"217","author":"Matsumoto","year":"2022","journal-title":"J\u00a0Pharm Biomed Anal"},{"key":"10.1016\/j.dmpk.2023.100530_bib12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-291X(75)90286-7","article-title":"The Gaucher mouse","volume":"67","author":"Kanfer","year":"1975","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.dmpk.2023.100530_bib13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.008185","article-title":"Animal models for Gaucher disease research","volume":"4","author":"Farfel-Becker","year":"2011","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.dmpk.2023.100530_bib14","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/ars.2015.6307","article-title":"Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice","volume":"23","author":"Rocha","year":"2015","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.dmpk.2023.100530_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1471-4159.1978.tb12395.x","article-title":"The Gaucher mouse: differential action of conduritol B epoxide and reversibility of its effects","volume":"30","author":"Stephens","year":"1978","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.dmpk.2023.100530_bib16","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","article-title":"Identification of modifier genes in a mouse model of Gaucher disease","volume":"16","author":"Klein","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.dmpk.2023.100530_bib17","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.4751","article-title":"Delineating pathological pathways in a chemically induced mouse model of Gaucher disease","volume":"239","author":"Vardi","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.dmpk.2023.100530_bib18","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/jnc.15136","article-title":"Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease","volume":"156","author":"Blumenreich","year":"2021","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.dmpk.2023.100530_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bcmd.2014.01.005","article-title":"Gaucher disease: plasmalogen levels in relation to primary lipid abnormalities and oxidative stress","volume":"53","author":"Moraitou","year":"2014","journal-title":"Blood Cells Mol Dis"},{"issue":"Suppl 1","key":"10.1016\/j.dmpk.2023.100530_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J\u00a0Neurochem"},{"key":"10.1016\/j.dmpk.2023.100530_bib21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13024-022-00554-8","article-title":"Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease","volume":"17","author":"Riboldi","year":"2022","journal-title":"Mol Neurodegener"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436723000423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:57:30Z","timestamp":1761163050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436723000423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":21,"alternative-id":["S1347436723000423"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100530","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitation and characterization of glucosylsphingosine in cerebrospinal fluid (CSF), plasma, and brain of monkey model with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2023.100530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100530"}}